Renaissance Technologies LLC lifted its position in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) by 21.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Renaissance Technologies LLC’s holdings in Lipocine were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Dimensional Fund Advisors LP acquired a new stake in Lipocine during the second quarter worth $98,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. StockNews.com cut Lipocine from a “buy” rating to a “hold” rating in a report on Saturday, September 28th. Alliance Global Partners started coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.
Lipocine Stock Down 1.2 %
Shares of NASDAQ LPCN opened at $5.14 on Friday. The business’s 50 day moving average is $4.26 and its two-hundred day moving average is $5.59. Lipocine Inc. has a 52-week low of $2.31 and a 52-week high of $11.79. The firm has a market cap of $27.49 million, a price-to-earnings ratio of -3.01 and a beta of 1.22.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million during the quarter. Analysts anticipate that Lipocine Inc. will post -0.92 EPS for the current fiscal year.
Lipocine Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- Compound Interest and Why It Matters When Investing
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- How Can Investors Benefit From After-Hours Trading
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding LPCN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lipocine Inc. (NASDAQ:LPCN – Free Report).
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
